lzheimer disease (AD) is the most common form of dementia affecting elderly people.' It is the fourth leading cause of death among adults in the United States, following heart disease, cancer, and stroke.' The prevalence of AD increases with increasing age. An estimated 10% of people aged 65 years have this progressive, degenerative disease, and this percentage increases to 47.2% for people aged 85 years and older."
As our population

Etiology
In the past decade, tremendous strides have been made in determining the n~iiltifactorial etiology of AD." Known risk factors for AD include age and genetic factor^.^,^ Other possible risk factors are level of education, female sex, history of head injury, exposure to heavy metals and toxins, positive family history, and trisomy 21.I.sG The characteristic neuropathologic findings of AD are senile or neuritic plaques, neurofibrillary tangles, loss of synaptic connections, and neuronal death in the cerebral cortex.',g-7
The prevalence of AD doubles with each decade after 65 years of a g e . T h e strongest support for a genetic basis of the disease comes from the fact that individuals with Down syndrome (trisomy 21) almost universally develop the neuropathologic symptoms of AD after age 40 years." Three genes have been found to be associated with the development of the early-onset familial form of AD, and one gene is considered a risk factor for the more common late-onset form of AD.1,"5z8zThe 4 genetic loci already known as contributing to AD do not appear to account for all of the genetic risk of the disease. Most recently, chromosome 12 is suspected of having a susceptibility gene for AD.I0
Most cases of AD occur in a sporadic, nongenetic fashion; only 5% to 10% of all cases of AD are familial. 6 Alzheimer disease is further divided into early-onset AD, a rare form of the disease with a mean age of onset below 65 years, or late-onset AD, with a mean age of onset at 65 years and older.' Therefore, the 4 subtypes of AD are early-onset familial, late-onset familial, early-onset sporadic, and late-onset sporadic.' The 3 autosomal dominant genes that account for all known cases of the early-onset familial form of AD are found on chromosomes 1, 14, and 21." Strong genetic evidence exists for familial AD; however, whether these genes actually cause the disease or merely represent a susceptibility or risk factors for AD is u n k n~w n .~ Mutations within the gene on chronlosome 21, which encodes for amyloid precursor protein (APP), the precursor of amyloid beta (AP) peptides, are associated with 2% to 3% of all cases of the early-onset familial form of AD. The presenilin 1 (PSI) gene located on chromosome 14 and the presenilin 2 (PS2) gene located on chron~osome 1 are linked to 70% to 80% and 20% to 25% of the early-onset familial form of AD, respectively. The commonality between these 3 genes (ie, APP, PSI, continues to age, Apolipoprotein E (apoE) is a serum lipoprotein involved in cholesterol metabolism that is encoded by a gene (APOE) on chromosome 19.' This is the only gene known to be associated with the more common lateonset forms of AD (familial and sporadic), accounting for 50% of the risk of AD.l,:j,"H~10 Apolipoprotein E has 3 different forms: E2, E3, and E4. It is the inheritance of the E4 allele that confers the risk. Individuals who are homozygous for the E4 allele (E4/E4) are more likely to develop and have an earlier age of onset of AD than are those individuals with other genotypes of the APOE alleles."ome carriers of the E4 allele, however, show no cognitive impairment,%nd people without the E4 allele can develop AD.'
Beyond the known risk factors of age and genetics are several suspected risk factors for AD. Education is thought to be somehow protective against The prevalence of AD is greater in women, with the risk increasing during the postmenopausal period. This fact probably explains why women who take estrogen have a lower prevalence of AD compared with women who do not take
The association ofAD with coronary artery disease, low body weight, and hip fractures, all of which relate to low estrogen levels, further suggests that low estrogen levels play a role in AD."lzheimer's disease occurs earlier in individuals who have a history of head injury with loss of c o n s c i o~s n e s s .~~~~~~ Exposure to heavy metals such as zinc and aluminum has also been explored as a possible risk factor for AD. Alunlinum is known to accumulate in the brain with normal Individuals with a positive family history of AD are at higher risk for the di~ease.',"~ This risk increases 4fold for individuals having 1 or more first-degree relatives with dementia, and it increases 40 times if 2 or more first-degree relatives have AD.j
Diagnosis
Dementia is "an impairment in cognitive function that is significant enough to interfere with the ability to conduct normal activities of daily l i~i n g . " l~( P~~) Alzheimer disease is the most common cause of dementia, accounting for 50% to 70% of cases.Is-' Dementia can be categorized as either reversible or irreversible.'~ome of the conlmon causes of irreversible dementia include degenerative diseases (eg, AD, Parkinson disease, multiple sclerosis), infections (eg, neurosyphilis, acquired immunodeficiency syndrome), vascular disease (eg, multi-infarct dementia, stroke, anoxia), and other possible causes (eg, head trauma, normal-pressure hydrocephalus, alcoholic dementia) .I6 Only 10% or less of the causes of dementia are reversible.14 The following Important diagnostic tools include interviews of both the patient and a reliable informant to gather information on the patient's current condition, medical and family history, time and mode of onset of deterioration, and any symptoms suggestive of coexisting medical, neurologic, or psychiatric p r~b l e m s . l~,~" l~ In addition to a comprel~ensive physical and neurologic examination, a screen of cognitive function, such as the Mini-Mental State Examination, should be a d m i n i~t e r e d . l "~~, l~
Cerebrospinal fluid (CSF) assays for tau proteins, which form the neurofibrillary tangles, and beta-amyloid peptides, which form the senile plaques, have also been developed.lY The CSF examination, however, is primarily used for relatively young or other atypical patients.'-' Cerebrospinal fluid assays "cannot stand alone in diagnosis but potentially can improve the accuracy of clinical diagnosis to above the 85% range and may allow us to diagnose and initiate treatment s~o n e r . "~!~( p~~'~)
The accuracy of imaging tools such as single photon emission computed tomography (SPECT), positron emission tomography (PET), computed tomography (CT), and magnetic resonance imaging (MRI) in the diagnosis of AD is c o n t r o~e r s i a l .~~~~~~~~~2~ Some researche r~~"~~ have reported the sensitivity and specificity of SPECT and CT to be too low to advocate the use of these tools independent of clinical evaluation in diagnosing AD. Due to the large overlap in information obtained from SPECT and CT, routine use of both tools is usually not justified.20
Although initially touted in the popular press, the use of tropicamide eyedrops for the diagnosis of AD is not reliable and study results have been ~onflicting.2~ The eyedrops reportedly caused pupil dilation in individuals with AD who are known to have acetylcholine deficiency because the iris sphincter is supersensitive to the cholinergic agent.21
A definite diagnosis of AD can only be made by biopsy or with specimens obtained at an autopsy; however, diagnostic accuracy during life is as high as 85% due to modern imaging and laboratory techniques and welldeveloped clinical ~r i t e r i a . l~-l~,~~
The gold standard for the diagnosis of AD continues to be the NINCDS-ADRDA criteria, which have a sensitivity of 80% to 100% and a specificity of 73% to 100%.20
Clinical Picture
Typically, 3 stages of AD are recognized.~Wccasionally, a fourth stage is identified.2Wach individual diagnosed with AD will exhibit certain symptoms, including loss of memory and intellectual ability. Generally, symptoms are more severe and an individual experiences a more rapid deterioration in cognitive and physical abilities with early-onset AD, as compared with late-onset AD.24 Table 2 lists the signs and symptoms noted in each stage of AD.24-26 Individuals, however, do not necessarily exhibit all of the signs and symptoms in each stage.
Therefore, no 2 individuals will present the signs and symptoms of AD identically. Several problems exhibited by individuals with AD in the areas of activities of daily living (ADL) , instrumental activities of daily living (IADL) , behavior, and cognition are noted in Table 3 .24-2" Plateaus in the course of progression of the illness Associated symptoms of depression; insomnia; incontinence; delusions; illusions; hallucinations; catastrophic verbal, emotional, or physical outburst; sexual disorders; and weight loss Other neurologic abnormalities in some patients, especially those with more advanced disease, including motor signs such as increased muscle tone, myoclonus, or gait disorder Seizures in advanced disease CT normal for age
Features that make the diagnosis of probable AD uncertain or unlikely:
Sudden, apoplectic onset Focal neurologic findings such as hemiparesis, sensory loss, visual field deficits, and incoordination early in the course of the illness Seizures or gait disturbances at the onset of symptoms or very early in the course of the illness
Diagnosis of possible AD:
May be made on the basis of the dementia syndrome; in the absence of other neurologic, sychiatric, or systemic disorders sufficient to cause dementia; and in the presence of variations in the onset, presentation, or clinicaTcourse May be made in the presence of a second systemic or brain disorder sufficient to produce dementia but not considered to be the cause of the dementia Should be used in research studies when a single, gradually progressive, severe cognitive deficit is identified in the absence of another identifiable cause
Criteria for diagnosis of definite AD:
Clinical criteria for probable AD Histopathologic evidence obtained from biopsy or autopsy Subtype classification for research purposes: linesterase (AChE) inhibitor that blocks the breakdown of a c e t y l~h o l i n e .~~-~~ The drug has been shown to improve cognitive function in patients with mild to moderate AD.5J7,30 Limitations associated with the use of tacrine, however, include gastrointestinal side effects, hepatotoxicity, and the need to take it 4 times a d a~. 2~-j l Another AChE inhibitor, donepezil (Aricept) , recently approved by the FDA, appears to have few systemic side effects and requires being taken only 1 time a day.I7,l9
Other AChE inhibitors and acetylcholine precursors are being investigated.Ig
Several other categories of drugs that have been investigated or that continue to be under investigation for the treatment of AD include anti-infla~nmatory medications, neurotrophic factors, estrogen, agents associated with protein processing, antioxidants, calcium channel blockers, and cholesterol-lowering drugs. Each of these categories of drugs will be discussed briefly.
~nti-inflammatory Medications
Proteins characteristic of the inflammatory process (eg, complement, inflammatory cytokines) are associated with amyloid plaques and neurofibrillary tang l e~. '~.~~ The fact that inflammation may contribute to neurodegeneration has led to the investigation of antiinflammatory substances, including nonsteroidal antiinflammatory agents (NSAIDs) and glucocorticoids, for protection against AD.5,19.28,m,32 A meta-analysis of epidemiological studies demonstrated a 50% to 75% reduction in AD development among persons taking NSAIDS.~~ A small group of patients with AD who were taking indomethacin showed no decline in cognitive function over a &month period in comparison with individuals receiving a placebo who showed a decline.3
Neurotrophic Factors
Neurotrophic factors, which are necessary for neuronal survival and development, may be insufficient in individuals with AD.5,28,30 Nenre growth factor (NGF), one of several neurotrophic factors studied, has been shown to enhance survival of cholinergic neurons in the basal forebrain and to demonstrate cognitive benefits in experimental animal m0dels.~0 These substances, however, do not cross the blood-brain barrier, creating a challenge for devising a safe way to administer these d r~g s .~.~~.~~ The best option, which has demonstrated cognitive benefits in aged animals, may be the use of an oral agent, such as AIT-082, that crosses the blood-brain barrier and stimulates the production of NGF.So tion to the known benefits of estrogen in preventing heart disease, osteoporosis, and stroke, the data supporting the use of estrogen in the prevention and treatment of AD is e n c o~r a g i n g .~~ The risk of breast and endometrial cancer with estrogen therapy, however, must be considered on an individual basis.Zg
Protein Processing Agents
Medications that would help prevent the deposition of amyloid plaques and the accumulation of tau proteins, which form the neurofibrillary tangles, would target the characteristic lesions of AD.2R,30
Antioxidants
Free radicals, which are by-products of oxygen metabolism, are molecules with an unpaired electron in their outer she11. 5, 28, 30 This reactive oxygen species might be responsible for the neuronal degeneration associated with aging and AD."JO Potential therapeutic agents include the enzymes superoxide dismutase and catalase, the antioxidants vitamins E and C, idebenone, and the selective monoamine oxidase-B inhibitor selegiline (Deprenyl).5,17,2",90 In a study conducted by the Alzheimer's Disease Cooperative Study Consortiurn,28.30 vitamin E and selegiline were given alone and in combination to individuals with moderate AD over a 2-year period. Results of the study are pending.28,30
Cakium Channel Blockers
Aging is associated with an increase in calcium channels in neurons.29 Calcium channel blockers work to prevent the calcium influx into nerve cells that leads to their death.5,28,30 In a study of young rats versus old rats, the calcium ion channel density was found to be 3 times greater in the older rats, which demonstrated poorer performance with learning tasks.z8 Furthermore, in some studies, the calcium channel blocker nimodipine slowed the decline of cognitive function in AD-type dementia.30
Treatment Strategies
Generally, the primary care physician, who is responsible for directing the care, as well as preventing and treating comorbid medical conditions of persons with AD, works in conjunction with professional and nonprofessional health care providers and the far nil^.]^,^^ All persons involved should recognize that treatment and care will be long term and that riot all individuals with AD will be i n s t i t~t i o n a l i z e d .~~.~~ The overall medical goals should be to maximize the person's abilities, rehabilitate lost 
Psychosocial Implications
of AD and to actually improve cognitive and affective Many areas such as AD education, legal and financial function in some with probable m.2~ 1, addiplanning (eg, durable power of attorney, living wills and trusts), support groups, and nursing home placement should be discussed with individuals who have AD when they are able to participate to some degree in those d i s c u s~i c~n s .~~~~~ The most difficult treatment decision for families is often when to place someone in a nursing home. 13 The stress of caring for someone with AD is extreme and often produces anxiety and depression among caregivers, which can lead to the use and abuse of psychotropic medications. 16 These medications may impair a caregiver's cognitive function, resulting in possible harm to the person for whom care is being provided.16 Family education, counseling, and formal and informal support groups are imperative for the emotional and physical well-being of caregiver^.^^
Conclusion
As life expectancy continues to increase, AD will become an even greater concern to our society. Research is helping to unravel the complex nature of the etiology of this disease. Great strides have been made in the diagnosis of AD and in the treatment of individuals with AD. The role of physical therapy in the diagnosis of AD and in the treatment of people with AD has not been evaluated with clinical research. In view of the needs of individuals with AD, however, physical therapists could be integral members of the health care team involved in treating individuals with AD. The unique skills that physical therapists possess may help to prevent loss of functional abilities. delav institutionalization. and enhance the overall quality of life for these individuals.
